News

Takeda's Dengue Shot is 80% Effective in Phase III Trial

Takeda's Dengue Shot is 80% Effective in Phase III Trial

Takeda has released results from a clinical trial that found its dengue shot was 95.4% effective in preventing dengue that required hospitalization; there were five hospitalizations in the vaccine group versus 53 in the placebo group. The company will submit these phase III results for regulatory approval. With clinical trials taking place in more than 200 countries worldwide, Yourway is the partner that companies need to navigate the diverse and ever-changing global regulatory landscape.

Back to Index
Media

Upcoming Event

Clinical Trial Supply Europe

March 11-12, 2020
Madrid, Spain
Booth #54

Media

Articles

The Evolving Demands of the Temperature-Controlled Supply Chain for Cell and Gene Therapy